THE INVESTOR

메뉴열기
October 24, 2019

SK Biopharm seeks USFDA’s approval for new drug candidate

PUBLISHED : November 26, 2018 - 12:47

UPDATED : November 26, 2018 - 12:47

  • 본문폰트 작게
  • 본문폰트 크게
  • 페이스북
  • 트위터
  • sms

[DISCLOSURE] SK (034730) announced on Nov. 26 that its subsidiary SK Biopharm has handed in new drug application for US Food and Drug Administration’s approval for its novel epilepsy drug candidate Cenobamate.  

By Hwang You-mee (glamazon@heraldcorp.com)

  • 페이스북
  • 트위터
  • sms
최상단으로
Herald Corporation|CEO : Kwon Chung Won
Publisher. Editor : Kwon Chung Won
Chief Privacy Officer & Juvenile Protection Manager : Yang Sung-jin
Title : The Investor|Date of registration : 2015.04.28
Company Registration No. 104-81-06004
Mail-Order Business Registration 2016 - Seoul Yongsan - 00590
Huam-ro 4-gil 10, Yongsan-gu, Seoul, Korea
T : +82-2-727-0114|Business info
Gov’t registration No. Seoul 아04099
COPYRIGHT HERALD CORPORATION. ALL RIGHTS RESERVED.